A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | MicrobiomeTrials
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-12-12Est. Completion: 2028-03-24
Enrollment target: 1,250 participants
Locations
GSK Investigational Site, Arcadia, California, United States
GSK Investigational Site, Covina, California, United States
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, San Diego, California, United States
GSK Investigational Site, Santa Maria, California, United States
GSK Investigational Site, Van Nuys, California, United States
GSK Investigational Site, Boynton Beach, Florida, United States
GSK Investigational Site, Cape Coral, Florida, United States
GSK Investigational Site, Doral, Florida, United States
GSK Investigational Site, Hialeah, Florida, United States
GSK Investigational Site, Homestead, Florida, United States
GSK Investigational Site, Inverness, Florida, United States
GSK Investigational Site, Jacksonville, Florida, United States
GSK Investigational Site, Kissimmee, Florida, United States
GSK Investigational Site, Lakeland, Florida, United States
GSK Investigational Site, Maitland, Florida, United States
Other microbiome trials you might be interested in